Approved September 1997
The U.S. Food and Drug Administration (FDA) approved Serevent for the maintenance treatment of asthma and in the prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease. This includes patients with symptoms of nocturnal asthma, who require regular treatment with inhaled, short-acting beta2-agonists.
The Serevent drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.